ImmunityBio (IBRX) EBIAT (2016 - 2025)
Historic EBIAT for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$67.3 million.
- ImmunityBio's EBIAT rose 2154.82% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 4068.64%. This contributed to the annual value of -$413.6 million for FY2024, which is 2915.24% up from last year.
- Latest data reveals that ImmunityBio reported EBIAT of -$67.3 million as of Q3 2025, which was up 2154.82% from -$92.6 million recorded in Q2 2025.
- Over the past 5 years, ImmunityBio's EBIAT peaked at -$59.2 million during Q4 2024, and registered a low of -$233.4 million during Q4 2023.
- For the 5-year period, ImmunityBio's EBIAT averaged around -$108.1 million, with its median value being -$95.6 million (2023).
- Per our database at Business Quant, ImmunityBio's EBIAT plummeted by 18492.78% in 2021 and then skyrocketed by 7464.63% in 2024.
- ImmunityBio's EBIAT (Quarter) stood at -$91.6 million in 2021, then dropped by 18.32% to -$108.3 million in 2022, then crashed by 115.47% to -$233.4 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then dropped by 13.68% to -$67.3 million in 2025.
- Its last three reported values are -$67.3 million in Q3 2025, -$92.6 million for Q2 2025, and -$129.7 million during Q1 2025.